Published in BMC Immunol on August 11, 2011
Investigating the Effect of Different Treatments with Lactic Acid Bacteria on the Fate of Listeria monocytogenes and Staphylococcus aureus Infection in Galleria mellonella Larvae. PLoS One (2016) 0.77
Development of Streptococcus pneumoniae Vaccines Using Live Vectors. Vaccines (Basel) (2014) 0.77
Pretreatment with a heat-killed probiotic modulates monocyte chemoattractant protein-1 and reduces the pathogenicity of influenza and enterovirus 71 infections. Mucosal Immunol (2016) 0.76
Mucosal immunity and vaccines. Nat Med (2005) 5.44
Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog (2008) 4.05
Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest (2009) 3.16
New horizons in adjuvants for vaccine development. Trends Immunol (2008) 2.85
NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol (2004) 2.71
Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis (2000) 2.55
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis (1997) 2.50
Mechanism of action of clinically approved adjuvants. Curr Opin Immunol (2009) 2.06
New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine (1994) 1.96
Childhood pneumonia mortality--a permanent global emergency. Lancet (2007) 1.73
Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med (2009) 1.67
Th1 memory: implications for vaccine development. Immunol Rev (2006) 1.58
Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents (2008) 1.52
The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol (2006) 1.50
Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol (2007) 1.43
Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr (2005) 1.43
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun (2010) 1.22
Lactobacillus casei improves resistance to pneumococcal respiratory infection in malnourished mice. J Nutr (2005) 1.19
Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol (2009) 1.18
Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomy-fed infant rats. Pediatr Res (2009) 1.15
Live bacterial vaccines--a review and identification of potential hazards. Microb Cell Fact (2006) 1.14
Humoral immune defense (antibodies): recent advances. Proc Am Thorac Soc (2005) 1.14
The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun (2010) 1.14
Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis (2006) 1.13
Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine (2003) 1.10
The global epidemiology of childhood pneumonia 20 years on. Bull World Health Organ (2008) 1.10
Daily intake of heat-killed Lactobacillus plantarum L-137 augments acquired immunity in healthy adults. J Nutr (2006) 1.08
Th17 cytokines and vaccine-induced immunity. Semin Immunopathol (2010) 1.07
Effect of intranasal administration of Lactobacillus casei Shirota on influenza virus infection of upper respiratory tract in mice. Clin Diagn Lab Immunol (2001) 1.04
Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect (2006) 1.00
Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naïve and malaria-exposed individuals. Infect Immun (2006) 0.99
Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One (2010) 0.98
Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect Immun (2008) 0.98
Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection in mice. Microbes Infect (2006) 0.95
PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infect Immun (2005) 0.95
Regulation of production of mucosal antibody to pneumococcal protein antigens by T-cell-derived gamma interferon and interleukin-10 in children. Infect Immun (2006) 0.94
Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes Infect (2008) 0.94
Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Microbiol Immunol (2008) 0.91
Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect Immun (2002) 0.89
Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin Exp Immunol (2009) 0.87
Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection. Can J Microbiol (2008) 0.86
Effect of Lactobacillus casei and yogurt administration on prevention of Pseudomonas aeruginosa infection in young mice. J Food Prot (2001) 0.86
Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice. FEMS Immunol Med Microbiol (2011) 0.86
Diversity of pneumococcal surface protein A (PspA) among prevalent clones in Spain. BMC Microbiol (2009) 0.85
Nasal vaccination induces protective immunity without immunopathology. Clin Exp Immunol (2002) 0.85
Enhanced immune response to pneumococcal infection in malnourished mice nasally treated with heat-killed Lactobacillus casei. Microbiol Immunol (2009) 0.85
Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Can J Microbiol (2008) 0.83
Influence of the oral administration of lactic acid bacteria on iga producing cells associated to bronchus. Int J Immunopathol Pharmacol (2003) 0.83
Protective effect of intranasally inoculated Lactobacillus fermentum against Streptococcus pneumoniae challenge on the mouse respiratory tract. FEMS Immunol Med Microbiol (2001) 0.83
Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections. Bioeng Bugs (2011) 0.80